Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy

doi:10.3748/wjg.v28.i27.3297

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5114)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

368

WORD

HTML

2792

Figures (1-1)

411

Tables (1-4)

383

Sum=4043

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

348

Download

723

Sum=1071

Jul 21, 2022 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 21, 2022; 28(27): 3297-3313
Published online Jul 21, 2022. doi: 10.3748/wjg.v28.i27.3297

Table 3 Complete adoptive cell transfer-based clinical trials in pancreatic ductal adenocarcinoma

Treatment	Phase	Number	Cancer stage	Outcomes
MORAb-009, Gemcitabine	II	NCT00570713	Advanced PDAC	MORAb-009 did not show survival benefit over placebo group [median OS 6.5 mo, 95%CI: 4.5–8.10 mo vs 6.9 mo 95%CI: 5.4–8.8 mo]
MORAb-009	I	NCT00325494	PDAC	No results reported yet
Radiolabeled Amatuximab (MORAb-009)	I	NCT01521325	PDAC	No results reported yet
Autologous Redirected RNA Mesothelin CAR T cells	I	NCT01897415	PDAC	No results reported yet
CART-133 T cells	I/II	NCT02541370	Relapsed and/or Chemotherapy Refractory Advanced PDAC	No results reported yet

https://clinicaltrials.gov/. PDAC: Pancreatic ductal adenocarcinoma; OS: Overall survival.

Citation: Smith C, Zheng W, Dong J, Wang Y, Lai J, Liu X, Yin F. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy. World J Gastroenterol 2022; 28(27): 3297-3313
URL: https://www.wjgnet.com/1007-9327/full/v28/i27/3297.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i27.3297